--- title: "Tela Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.06 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286151752.md" datetime: "2026-05-12T20:21:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286151752.md) - [en](https://longbridge.com/en/news/286151752.md) - [zh-HK](https://longbridge.com/zh-HK/news/286151752.md) --- # Tela Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 19.06 M Revenue: As of FY2026 Q1, the actual value is USD 19.06 M, beating the estimate of USD 19 M. EPS: As of FY2026 Q1, the actual value is USD -0.21, missing the estimate of USD -0.19. #### First Quarter 2026 Financial Results #### Revenue TELA Bio, Inc. reported revenue of $19.1 million in the first quarter of 2026, representing a 3% growth over the same period in 2025 . Specifically, revenue was $19,059 thousand in Q1 2026, compared to $18,520 thousand in Q1 2025, with unit growth of 13% year-over-year . European revenue growth accelerated to 41% over the prior year period . #### Gross Profit and Margin Gross profit for the first quarter of 2026 was $12,520 thousand, or 65.7% of revenue, compared to $12,512 thousand, or 67.6% of revenue, in the same period in 2025 . The decrease in gross margin was primarily due to a higher charge for excess and obsolete inventory as a percentage of revenue . Gross margin remained around 65% for Q2 2023 through Q1 2026 . #### Operating Expenses Total operating expenses were $23,046 thousand in the first quarter of 2026, a slight increase from $22,984 thousand in the first quarter of 2025 . Sales and marketing expenses were $16,537 thousand in Q1 2026, compared to $16,608 thousand in Q1 2025 . General and administrative expenses were $4,166 thousand in Q1 2026, up from $3,836 thousand in Q1 2025 . Research and development expenses were $2,343 thousand in Q1 2026, down from $2,540 thousand in Q1 2025 . #### Loss from Operations Loss from operations was -$10,526 thousand in the first quarter of 2026, compared to -$10,472 thousand in the same period in 2025 . #### Net Loss Net loss was -$12,273 thousand in the first quarter of 2026, compared to a net loss of -$11,264 thousand in the same period in 2025 . #### Cash and Cash Equivalents Cash and cash equivalents totaled $39,541 thousand on March 31, 2026, down from $50,845 thousand on December 31, 2025 . As of March 31, 2026, cash and cash equivalents totaled $39.5 million . #### Other Financial Data - Interest expense was -$2,053 thousand in Q1 2026, compared to -$1,219 thousand in Q1 2025 . - Other income was $366 thousand in Q1 2026, compared to $479 thousand in Q1 2025 . - Loss before income tax expense was -$12,213 thousand in Q1 2026, compared to -$11,212 thousand in Q1 2025 . - Income tax expense was -$60 thousand in Q1 2026, compared to -$52 thousand in Q1 2025 . #### Operational Metrics - **Product Adoption**: As of May 2026, TELA Bio, Inc. has achieved approximately 90,000 OviTex Reinforced Tissue Matrix (RTM) implantations globally and around 20,000 OviTex PRS implantations in the U.S. . The company has 70+ published or presented works related to OviTex and OviTex PRS, and over 1,500 patients have been included in peer-reviewed publications . TELA Bio, Inc. also has GPO access covering over 5,000 hospitals . - **Market Opportunity**: The total U.S. market opportunity is estimated at $2.6 billion, comprising $1.8 billion for hernia and abdominal wall reconstruction and $0.8 billion for plastic reconstructive surgery . The U.S. hernia surgery market represents an annual opportunity of $1.8 billion, with robotic/minimally invasive surgery (MIS) compatible procedures accounting for over 1 million annually and a potential market opportunity of up to $1.2 billion . The U.S. plastic and reconstructive surgery market presents an annual opportunity of approximately $800 million . #### Outlook / Guidance TELA Bio, Inc. reiterated its full year 2026 revenue guidance, projecting at least 8% growth over full year 2025 . The company expects second quarter 2026 revenue to be approximately $20.0 million . Gross margin is expected to remain around 65% through Q1 2026 . ### Related Stocks - [TELA.US](https://longbridge.com/en/quote/TELA.US.md) ## Related News & Research - [TELA Bio Q1 revenue growth beats estimates, loss widens](https://longbridge.com/en/news/286151902.md) - [TELA Bio (TELA) Projected to Post Earnings on Tuesday](https://longbridge.com/en/news/285248776.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)